Patrick W. Burke

Automatic Code Generation Through Model-Driven Design

Philip H. Sweany, Patrick W. Burke, P. Sweany, 2007 .

DEVELOPMENT OF TEST PARADIGMS F OR OPERANT C ONDITIONING OF WILD NORWAY RAT S

Patrick W. Burke, Susan M. Jojola, P. Burke, 2007 .

Acute Lymphoblastic Leukemia, Version 2.2015.

Patrick W. Burke, A. Zelenetz, O. Frankfurt, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Acute Lymphoblastic Leukemia, Version 2.2015.

Patrick W. Burke, Andrew D. Zelenetz, Patricia Aoun, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.

Patrick W. Burke, D. Bixby, Anthony J. Perissinotti, 2021, Leukemia research.

Utility of methicillin‐resistant Staphylococcus aureus (MRSA) nasal screening in patients with acute myeloid leukemia (AML)

Patrick W. Burke, D. Bixby, Gianni B. Scappaticci, 2021, Transplant infectious disease : an official journal of the Transplantation Society.

Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis

Patrick W. Burke, A. Chinnaiyan, D. Robinson, 2017, American journal of hematology.

Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.

Patrick W. Burke, S. Devlin, M. Tallman, 2018, Leukemia research.

Acute Lymphoblastic Leukemia, Version 2.2021

Patrick W. Burke, A. Logan, M. Liedtke, 2021 .

Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome

Patrick W. Burke, Anthony J. Perissinotti, B. Marini, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.

Patrick W. Burke, O. Frankfurt, H. Kantarjian, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Partial tandem duplication of KMT2A (MLL) may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome

Patrick W. Burke, Lina Shao, R. Dewar, 2018, Haematologica.